Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
about
Identification of sialylated glycoproteins from metabolically oligosaccharide engineered pancreatic cells.Nutrient-deprived cancer cells preferentially use sialic acid to maintain cell surface glycosylation.Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids.Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells.Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes.
P2860
Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Metabolic glycoengineering sen ...... itors erlotinib and gefitinib.
@en
type
label
Metabolic glycoengineering sen ...... itors erlotinib and gefitinib.
@en
prefLabel
Metabolic glycoengineering sen ...... itors erlotinib and gefitinib.
@en
P2093
P2860
P1476
Metabolic glycoengineering sen ...... itors erlotinib and gefitinib.
@en
P2093
Christopher T Saeui
Elaine Tan
Kevin J Yarema
Lingshu Liu
Rahul Bhattacharya
P2860
P304
P356
10.1016/J.BMCL.2015.01.060
P407
P577
2015-02-04T00:00:00Z